Dr. Sengun is the founder and the medical director of the Sengun Neuromodulator and Aesthetic Medicine Clinic a.k.a Sengun Aesthetics. Dr. Sengun began injecting different types of botulinum toxins for a wide range of treatments in the fields of Neurology and Aesthetics in 2006 and has been on advisory boards for companies like Allergan, Ispen, and Merz.
Through these years of experience, vast knowledge, meticulous detail, as well as sophisticated injections techniques he has mastered and combined the art of sculpting the face and body. He has used these to his advantage to achieve the best natural outcomes in non-surgical enhancements of the face and body in women and men leading to full satisfaction in your beauty and appearance. He has received training from multiple world-renowned international plastic surgeons.
Dr. Sengun is also a Parkinson’s Disease, Movement Disorders and Neuromodulator treatment specialist. Currently he is at Mount Sinai Medical Center in Miami Beach and at Florida Center for Parkinson’s Disease and Movement Disorders in Boca Raton, Florida as the medical director.
He is also the medical director at the Parkinson’s Foundation South Palm Beach Chapter. Previously he was assistant professor at University of Miami Miller School of Medicine Parkinson’s Disease and Movement Disorders Center –NPF Center of Excellence and the Director of Outreach Program. During his years at the University of Miami he participated in many research studies, co-authored in multiple papers and taught medical students, residents and fellows. He has also been a consultant and speaker for multiple pharmaceutical companies like Lundbeck, Teva, and USWorldmeds.
Cenk Sengun, MD – BIO
Medical Director and Founder, Sengun Neuromodulator and Aesthetic Medicine Clinic a.k.a Sengun Aesthetics; 2015 to present
Medical Director, National Parkinson’s Foundation South Palm Beach Chapter
Boca Raton, Florida; 2010 to present
Florida Center for Neurology, Parkinson’s Disease and Movement Disorders,
Medical Director and Founder
Boca Raton, Florida; March 06, 2013 to present
Miami Beach, Florida; March 06, 2014 to present
Mount Sinai Medical Center,
Department of Neurology – Staff
Miami Beach, Florida; March 06, 2013 to present
Faculty, Assistant Professor of Neurology, University of Miami Miller School of
Medicine Parkinson’s disease and Movement Disorders Center-
NPF Center of Excellence (COE)
Miami, Florida; July 01, 2009 to March 05, 2013
Director of Outreach Program, University of Miami Miller School of
Medicine Parkinson’s disease and Movement Disorders Center-
NPF Center of Excellence (COE)
Miami, Florida; July 01, 2009 to March 05, 2013
Faculty, Clinical Instructor of Neurology, University of Miami Miller School of
Medicine Parkinson’s disease and Movement Disorders Center-
NPF Center of Excellence (COE)
Miami, Florida; August 11, 2008 to June 31, 2009.
Fellow, Movement Disorders Division, University of Miami Miller School of
Medicine Parkinson’s disease and Movement Disorders Center-
NPF Center of Excellence (COE)
Miami, Florida; June 2006 to August 2008
Neurology Resident, Department of Neurology, University of Miami Miller School
of Medicine/Jackson Memorial Hospital
Miami, Florida; 2002 to 2006
Research Associate, Department of Neurology, University of Miami Miller School
of Medicine
Miami, Florida 2000-2002
Submitted peer review papers
1. R Lopez-Alberola, D Lorenzo, MA Gonzalez, C Sengun, C Singer, S
Papapetropoulos, Encephalitis lethargica: a reawakening from the past.
(Neurology 2007)
2. Spyridon Papapetr opoulos, Silvia Delgado, Cenk Sengun, Carlos Singer.
“Parkinsonism/dystonia syndrome secondary to multiple sclerosis with anti-basal
ganglia antibodies” (Movement Disorders 2008)
Peer reviewed posters
1. S Papapetropoulos, BVGallo, J Jagid, J Zitser, C Sengun, C Singer. Peri- and intra-operative electronic monitoring of tremor STN DBS for Parkinson s disease. Poster session presented at the annual meeting of the American Academy of Neurology, Boston, MA.
2. S Papapetropoulos, J Jagid, N Ahmad, J Zitser, C Sengun, C Singer, BV Gallo. Low rate of complications with unilateral STN-DBS in advanced Parkinson’s disease. The Movement Disorder Society’s 11th International Congress of Parkinson’s disease and Movement Disorders.
3. S Papapetropoulos, J Jagid, C Sengun, C Singer, B V Gallo. Objective monitoring of tremor and bradykinesia during deep brain stimulation of STN for Parkinson’s disease: A pilot study. The Movement Disorder Society’s 11th International Congress of Parkinson’s disease and Movement Disorders.
4. S Papapetropoulos, S Baez, J Zitser, C Sengun, C Singer. Retrocollis: classification, clinical phenotype, treatment outcomes and risk factors. The Movement Disorder Society’s 11th International Congress of Parkinson’s disease and Movement Disorders.
5. S Papapetropoulos, J Friedman, C Blackstone, GI Kleiner, C Sengun, C Singer. A progressive, fatal dystonia-parkinsonism syndrome in a patient with primary immunodeficiency receiving chronic IVIG therapy. The Movement Disorder Society’s 11th International Congress of Parkinson’s disease and Movement Disorders.
6. A. Tuchman, C. Sengun, A. Russell, C. Singer, S. Papapetropoulos. Anterocollis: Classification, Clinical Phenotype, Treatment Outcomes and Risk Factors. Twenty First Annual Symposium on Etiology, Pathogenesis, and Treatment of Parkinson’s Disease and Other Movement Disorders Movement Disorders, Vol. 22, No. 12, 2007 1.
7. Spyridon Papapetropoulos, Alexandra Guevara, Blake Scanlon, Cenk Sengun, Angela Russell, Bonnie Levin, Heather Katzen, Carlos Singer. Reaction time (RT) as a clinical marker in Parkinson’s disease. Movement Disorder Society 2008.
Articles Accepted for Publication:
Accepted peer reviewed papers
1. D.M. Wallace, S. Shafazand, D.Z. Carvalho, F.B. Nahab, C. Sengun, A Russell, H.B Moore, C.Singer, Sleep Related Falling Out of Bed in Parkinson’s disease. Journal of Clin. Neurology 2012, March :8 (1): 51-57
2. S Papapetropoulos, A Tzakis, C Sengun, C Reddy MD, K Boukas, J Zitser, C Singer. A case of pediatric acquired chronic hepatocerebral degeneration. Pediatric Neurology 38:67-70.
3. S Papapetropoulos, S Baez, J Zitser, C Sengun, C Singer Retrocollis: classification, clinical phenotype, treatment outcomes and risk factors. Eur Neurol. 2007 Oct 4; 59(1-2):71-75.
4. Papapetropoulos S, Jagid JR, Sengun C, Singer C, Gallo BV. Objective monitoring of tremor and bradykinesia during DBS surgery for Parkinson disease. Neurology. 2008 Apr 8;70(15):1244-9. PMID: 18391156 [PubMed – indexed for MEDLINE]
5. Papapetropoulos S, Singer C, Sengun C, Gallo BV. Giant arteriovenous malformation presenting as pediatric task-specific dystonia. Neurology. 2008 Apr 8;70(15):1294. No abstract available. PMID: 18391163 [PubMed – indexed for MEDLINE].
6. Eisa M, Singer C, Sengun C, Russel A, Jabbari B, Papapetropoulos S. Treatment of painful limbs/moving extremities with botulinum toxin type A injections. Eur Neurol. 2008;60(2):104-6. Epub 2008 Jun 14. No abstract available. PMID: 18552499 [PubMed – indexed for MEDLINE].
7. Papapetropoulos S, Tuchman A, Sengun C, Russell A, Mitsi G, Singer C. Anterocollis: clinical features and treatment options. Med Sci Monit. 2008 Sep;14(9):CR427-30. PMID: 18758411 [PubMed – indexed for MEDLINE].
8. Delgado S, Baez S, Singer C, Sengun C, Sheremata WA, Papapetropoulos S.
Parkinsonism/dystonia syndrome secondary to multiple sclerosis with antibasal ganglia antibodies. Mov Disord. 2009 Jan 30;24(2):309-11. No abstract available. PMID: 18951536 [PubMed – in process]
9. Papapetropoulos S, Argyriou AA, Guevara A, Sengun C, Mitsi G, Singer C.
Hemifacial Spasm and Pontine Compression Caused by a Giant Vertebrobasilar Dolichoectasia. Cerebrovasc Dis. 2009 Mar 18;27(4):413-414. [Epub ahead of print] No abstract available. PMID: 19295203 [PubMed – as supplied by publisher NNn
10. Patrycja M. Dubielecka, Nelson Hwynn, Cenk Sengun, Soohee Lee, , Christine Lomas-Francis, Carlos Singer, Hubert Fernandez,
Ruth H Walker
Two McLeod patients with novel mutations in XK Journal of the neurological sciences 305(1-2):160-4 April 2011
11. N. Usmani, Gurdesh S Bedi, C Sengun, A Pandey, Carlos Singer
Late onset of cervical dystonia in a 39-year-old patient following cerebellar hemorrhage Journal Neurology 258(1):149-51 January 2011
12. C.Singer, H. Moore, C. Sengun Hemidystonia and contralateral hemiballism following acute encephalitis by influenza a HINI virus and Mycoplasma pneumonia; A case report-Conference Paper14th International Congress of Parkinsons Disease and Movement Disorders-January 2010
13. Alexandra G. Guevara-Salcedo, Ajay Pandey, Fatta B Nahab, Cenk Sengun, Spyridon Papapetropoulos, Angela H. Russell, Carlos Singer
Solitary Parkinsonian signs in Essential Tremor may herald the eventual appearance of Parkinson Disease- Conference Paper- 61st Annual meeting of American- Academy of Neurology, Volume 72
V. PROFESSIONAL
Funded Research Performed:
Co-Investigator:
CD PROBE – Cervical Dystonia – Patient Registry for Observation of
BOTOX® Efficacy, Allergan, Inc., 2009 – 2011.
STEADY-PD: A Pilot Phase II Double- Blind, Placebo Controlled, Tolerability and
Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients
with Early Parkinson Disease, Michael J. Fox Foundation and Northwestern
Dixon Foundation, 2009 – 2011.
Participating Investigator:
A Randomized Trial to Evaluate Ampyra for Gait Impairment in Parkinson’s Disease, Acorda Therapeutics Inc., 2011 – 2013.
Protocol # SYN115-CL02: A double-blind, randomized, placebo-controlled study of the safety and efficacy of SYN115 as adjunctive therapy in levodopa-treated Parkinson’s subjects with end of dose wearing off, Synosia Therapeutics, Inc., 2011 – 2013.
URGE-PD: A Multi-site, Double-blind, Randomized, Placebo controlled trial of Solifenacin succinate (VESIcare) for the Treatment of Overactive Bladder in Parkinson’s Disease, University of South Florida, 2011 – 2013.
A Multi-Center, Double-Blind, Placebo-Controlled Phase II Study of Pioglitazone in Early Parkinson’s Disease (FS-ZONE), NIH/NINDS, 2011 – 2013.
A Multi-Center, Double-Blind, Randomized, Parallel Group Tolerability Study of coenzyme Q10 (UbiquinonE) in PRE-manifest Huntington’s Disease (PREQUEL), NIH/NINDS, 2011 – 2013.
Protocol No. IPX066-B09-06: A Study to Compare IPX066 and
Carbidopa/Levodopa/Entacapone (CLE) in Advanced Parkinson’s Disease, Impax Laboratories, Inc., 2010 – 2013.
Effects of Coenzyme Q10 in Parkinson Disease (QE3) Protocol # U01 NS050324-01A1 Phase III, National Institutes of Health, 2008 – 2011.
Protocol # TVP-1012/501 (ADAGIO): An Open-label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson’s Disease Subjects who Participated in the ADAGIO Study , Teva Pharmaceutical Industries LTD., 2009 – 2014.
Protocol 2CARE-01.00: Coenzyme Q10 (CoQ) in Huntington’s Disease (2CARE), National Institutes of Health, 2008 – 2014.
Protocol # SP921 – A multicenter, randomized, double-blind, placebo-controlled, 5-arm, parallel-group study to assess rotigotine transdermal system dose response in subjects with advanced-stage Parkinson’s disease, SCHWARZ Biosciences, Inc., 2008-2011.
Protocol # NET-PD LS-1 – A Multicenter, Double-Blind, Parallel Group, Placebo Controlled Study of Creatine in Subjects with Treated Parkinson’s Disease (PD). Long-term Study – 1 (LS-1) National Institute of Neurological Disorders and Stroke (NINDS), 2006 -2011.
Protocol # 248.538 – A Two Year Open Label, Randomized, Parallel Group, Blinded Assessment Ophthalmologic Safety Study of Pramipexole IR versus Ropinirole in Early Parkinson’s Disease Patients, Boehringer Ingelheim Pharmaceuticals, Inc., 2005 – 2010.
APLIED Neurogen Aplindore-211 Protocol: A Randomized, Double Blind,
Placebo Controlled Study to Assess the Efficacy and Safety of Three Doses
of Aplindore MR (1, 3, and 6 mg Twice Daily) in Patients with Early Parkinson
Disease, Neurogen Corporation, 2008 – 2009.
Protocol # SNT-II-004 – A Phase II, Randomized, Double-Blind, Placebo-
Controlled, Dose Response Study of the Efficacy, Safety and Tolerability of
Fipamezole as an Oromucosal Fast Dissolving Tablet in the Treatment of
Parkinson’s Disease Patients, JUVANTIA Pharma Ltd., 2008 – 2009.
Protocol # MRZ 60201-0408 – Prospective, double-blind, placebo-controlled, randomized, multi‑center trial with a double-blind parallel-group extension period to investigate the efficacy and safety of different doses of NT 201 in the treatment of cervical dystonia, Merz Pharmaceuticals GmbH, 2006 – 2009.
Protocol # MRZ 60201-0433 – Prospective, double-blind, placebo-controlled, randomized, multi‑center trial with an open-label extension period to investigate the efficacy and safety of NT 201 in the treatment of blepharospasm, Merz Pharmaceuticals GmbH, 2006 – 2009.
Residency Research Project, Cyanobacteria Toxin (BMAA) in Postmortem brain tissue and hair samples of ALS patients; 2005 – 2013.
Protocol # ACP-103-012 – A Multi-Center, Open-Label Extension Study to
Examine the Safety and Tolerability of ACP-103 in the Treatment of Psychosis
In Parkinson’s Disease, ACADIA Pharmaceuticals Inc., 2008 – 2009
ACADIA OL Protocol # ACP-103-015: A Multi-Center, Open-Label Extension Study to Examine the Safety and Tolerability of ACP-103 in the Treatment of Psychosis in Parkinson’s Disease, ACADIA Pharmaceuticals, Inc., 2008 – 2009.
Protocol # 248.622 – A randomized, double-blind, active (pramipexole 0.5 mg tid)
And placebo controlled, efficacy study of pramipexole given 0.5 mg and 0.75 mg bid over a 12-week treatment phase in early Parkinson’s disease patients (PramiBID), Boehringer Ingelheim Pharmaceuticals, Inc., 2007 – 2009.
Protocol # E2007-A001-303 – A Multi-centre, Open Label Extension Study to Evaluate the Long‑term Safety, Tolerability, and Efficacy of E2007 as an Adjunctive Therapy in Levodopa Treated Parkinson’s Disease Patients with Motor Fluctuations, Eisai Medical Research Inc., 2007 – 2008.
Protocol # E2007-A001-302 – A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy, Safety, and Tolerability of E2007 in Levodopa Treated Parkinson’s Disease Patients with Motor Fluctuations, Eisai Medical Research Inc., 2006 – 2008.
Research Associate in Mitochondrial Genetics Research Lab, to investigate mechanisms of neurotoxicity of Antiretroviral drugs in Guinea pig model; October 26, 2000 – June 30, 2002.
Unfunded Research
Billing, Coding and Reimbursement in Parkinson’s Disease, 2010 – 2013.
Umbrella: Natural history study of neurological movement disorders, 2009 – 2013.
Focal or Segmental Dystonia. Clinical Characteristics and Treatment Outcomes, 2005 – 2009.
Retrospective Chart Review of Patient’s with Parkinson’s Disease, 2006 – 2009.
Tremor, Sway and Reaction Time Electronic Recording in Patients with
Suspected or Diagnosed Movement Disorders, 2005 – 2010.
Validation of novel candidate gene markers in blood of Parkinson’s disease
patients and normal controls, 2006 – 2008.
Investigations of Hallucinations in Parkinson’s Disease Patients, 2006 – 2008.